Table 1.
Studies in the ‘Sormani data’ reporting the annualised relapse rate ratio and the disability progression rate ratio.
| Study | Contrast | Number | Follow-up | Annualised relapse | Disability progression |
|---|---|---|---|---|---|
| of patients | (months) | rate ratio | rate ratio | ||
| Paty (1) 1993 | IFNbeta-1b 1.6 MIU vs PBO | 248 | 24 | 0.92 (0.82, 1.03) | 1.00 (0.67, 1.49) |
| Paty (2) 1993 | IFNbeta-1b 8 MIU vs PBO | 247 | 24 | 0.66 (0.58, 0.75) | 0.71 (0.46, 1.12) |
| Miligan 1994 | Methylprednisolone vs PBO | 26 | 24 | 0.81 (0.50, 1.30) | 1.14 (0.26, 5.03) |
| Johnson 1995 | GA vs PBO | 251 | 24 | 0.71 (0.61, 0.82) | 0.88 (0.57, 1.35) |
| Jacobs 1996 | IFNbeta-1a 6 MIU vs PBO | 172 | 24 | 0.68 (0.57, 0.81) | 0.63 (0.38, 1.04) |
| Fazekas 1997 | IVIg vs PBO | 150 | 24 | 0.41 (0.34, 0.49) | 0.70 (0.36, 1.35) |
| Millefiorini 1997 | Mitoxantrone vs PBO | 51 | 24 | 0.34 (0.24, 0.47) | 0.19 (0.05, 0.78) |
| Achiron 1998 | IVIg vs PBO | 40 | 24 | 0.37 (0.27, 0.52) | 0.82 (0.19, 3.50) |
| Li (1) 1998 | IFNbeta1a 22 μg vs PBO | 376 | 24 | 0.71 (0.64, 0.78) | 0.81 (0.61, 1.08) |
| Li (2) 1998 | IFNbeta1a 44 μg vs PBO | 371 | 24 | 0.68 (0.62, 0.75) | 0.73 (0.54, 0.99) |
| Baumhackl 2005 | Hydrolytic enzymes vs PBO | 306 | 24 | 0.85 (0.74, 0.97) | 1.08 (0.74, 1.57) |
| Polman 2006 | NAT vs PBO | 942 | 24 | 0.32 (0.29, 0.36) | 0.59 (0.46, 0.75) |
| Comi (1) 2009 | Cladribine 3.5 mg/kg vs PBO | 870 | 24 | 0.42 (0.36, 0.49) | 0.69 (0.52, 0.93) |
| Comi (2) 2009 | Cladribine 5.25 mg/kg vs PBO | 893 | 24 | 0.45 (0.39, 0.52) | 0.73 (0.55, 0.97) |
| Sorensen 2009 | IFNbeta-1a and oral methylprednisolone | 130 | 24 | 0.37 (0.27, 0.50) | 0.64 (0.32, 1.28) |
| vs IFNbeta-1a and PBO | |||||
| Clanet 2002 | IFNbeta-1a 60 μg vs 30μg | 802 | 36 | 1.05 (0.99, 1.12) | 1.00 (0.84, 1.20) |
| Durelli 2002 | IFNbeta1b vs IFNbeta1a | 188 | 24 | 0.71 (0.59, 0.86) | 0.43 (0.24, 0.78) |
| Rudick 2006 | NAT + IFNbeta-1a vs IFNbeta-1a | 1171 | 24 | 0.45 (0.41, 0.49) | 0.79 (0.65, 0.96) |
| Coles (1) 2008 | ALE 12 mg vs IFNbeta-1a | 223 | 36 | 0.31 (0.24, 0.40) | 0.35 (0.16, 0.73) |
| Coles (2) 2008 | ALE 24 mg vs IFNbeta-1a | 221 | 36 | 0.22 (0.16, 0.30) | 0.38 (0.19, 0.76) |
| Mikol 2008 | IFNbeta vs GA | 764 | 24 | 1.03 (0.90, 1.17) | 1.34 (0.88, 2.06) |
| Havrdova (1) 2009 | IFNbeta-1a 30 μg plus AZA 50 mg | 118 | 24 | 0.87 (0.73, 1.04) | 1.23 (0.58, 2.62) |
| vs IFNbeta-1a 30 μg | |||||
| Havrdova (2) 2009 | IFNbeta-1a 30 μg IM plus AZA 50 mg plus | 123 | 24 | 0.70 (0.58, 0.85) | 1.04 (0.48, 2.27) |
| prednisone 10 mg vs IFNbeta-1a 30 μg | |||||
| O'Connor (1) 2009 | IFNbeta-1b 250 μg vs GA | 1345 | 24 | 1.06 (0.97, 1.16) | 1.05 (0.84, 1.31) |
| O'Connor (2) 2009 | IFNbeta-1b 500 μg vs GA | 1347 | 24 | 0.97 (0.88, 1.06) | 1.10 (0.88, 1.37) |
AZA: azathioprine; GA: glatiramer acetate; IFNβ: interferon-β; IVIg: IV immunoglobulin; PBO: placebo.